ArticleBlood advances2019
A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis.
Article in Blood advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy and toxicity of treatment of smoldering multiple myeloma: a systematic review and meta-analysis.Annals of medicine · 2025Pooled it
- Evaluating early intervention in smoldering myeloma clinical trials: a systematic review.The oncologist · 2025Pooled it
- Avelumab, a PD-L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma.The oncologist · 2021Trial
- Review
- Monoclonal gammopathy of undetermined significance in patients with solid tumours: Effects of immune checkpoint inhibitors on the monoclonal protein.British journal of haematology · 2025Article
- Monoclonal Antibodies in Smoldering Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance: Current Status and Future Directions.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Immune checkpoint blockade in hematological malignancies: current state and future potential.Frontiers in oncology · 2024Review
- Worth a Pound of Cure? Emerging Strategies and Challenges in Cancer Immunoprevention.Cancer prevention research (Philadelphia, Pa.) · 2023Review
- Smoldering multiple myeloma: Reviewing the rationale for intervention.Leukemia & lymphoma · 2022Article
- Checkpoint Inhibitors in Multiple Myeloma: Intriguing Potential and Unfulfilled Promises.Cancers · 2021Review
- 2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde.Haematologica · 2021Review
- Progress in the Management of Smoldering Multiple Myeloma.Current hematologic malignancy reports · 2021Review
- Clinical epigenetics settings for cancer and cardiovascular diseases: real-life applications of network medicine at the bedside.Clinical epigenetics · 2021Review
- Serum paraprotein persistence and size determine outcome in a cohort of patients with a modern definition of plasmacytoma with up to 19 years of follow up.Blood cancer journal · 2021Article
- What Is New in the Treatment of Smoldering Multiple Myeloma?Journal of clinical medicine · 2021Review
- Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease.Frontiers in immunology · 2021Article
- Review
- How we manage smoldering multiple myeloma.Hematology reports · 2020Article
- Exhausted and outnumbered: CD4+ T cells in the myeloma battlefield.Leukemia & lymphoma · 2020Article
- Review
Corrections and comments
- Erratum issued
Authors and funding
21 authors.
Funding
Abstract
Multiple myeloma is, in most patients, an incurable cancer. Its precursors can be identified with routine tests setting the stage for early intervention to prevent active myeloma. We investigated the efficacy and safety of pembrolizumab, an antiprogrammed cell death 1 antibody, in smoldering myeloma patients with intermediate/high risk of progression to symptomatic myeloma. Thirteen patients were treated with a median number of 8 cycles. One patient achieved a stringent complete response with bone marrow next-generation sequencing negativity at 10
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.